Wednesday, February 26, 2020 10:43:19 AM
Which is Breathtec now Algernon seemingly had plenty options upon the so called "acquistition" of Nash Pharma.
The narrative shoved down shareholders throat was 3 trials for $5 Million CAD + Research Use Only - Point of Care Breathalyzer (RUO POC).
The narrative ultimately got boiled down to 1 trial for $3.5 Million CAD (raised) & no RUO POC device ever - meaning never.
No matter what the narrative is coming out of Bullrun Capital for any of it's penny stock picks the end results are never on target.
Algernon has experienced the worst of these ever changing narratives cooked up by management over the years.
Meanwhile, pre split common shareholders risk everything at this point.
If the upcoming trial is unsuccessful the current losses upwards of 90% will be permanently wiped out.
That's what's at stake for many if not most here.
Therefore, the Clinical Trial Queen rules the day.
/////AMG
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM